Cognition Therapeutics advancing zervimesine for DLB psychosis after FDA Type C meeting

COGNITION THERAPEUTICS INC

Company plans to pursue registrational path for zervimesine (CT1812) to treat DLB psychosis, following FDA Type C meeting minutes.
Phase 2 SHIMMER data showed 86% slowing of decline on NPI-12 vs placebo; no motor function worsening.
No approved medications for DLB psychosis; traditional antipsychotics are contraindicated.
Next study will use validated endpoints for neuropsychiatric symptoms; patients randomized to 100 mg zervimesine or placebo.
Company expects to meet with FDA Division of Psychiatry by midyear 2026 to discuss the program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.